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Abstract
Objective: To assess the prognostic ability of lymphovascular invasion (LVI) as a predictor of overall survival (OS).
Materials and Methods: We included 126,682 prostate cancer (CaP) cM0 patients who underwent radical prostatectomy with lymph
node dissection between 2010 and 2015, within the National Cancer Database. Patients who received androgen deprivation therapy were
included. Patients were divided into four sub-cohorts based on LVI and lymph node invasion (LNI) status: pL0N0, pL1N0, pL0N1, and
pL1N1. Kaplan-Meier curves estimated OS and Cox-regression analysis tested the relationship between LVI and OS.
Results: Median (IQR) age and PSA at diagnosis were 62 (57-66) years and 5.7 (4.5-8.9) ng/ml, respectively. Most patients had pT2
stage (68.5%), and pathological Gleason 3+4 (46.7%). 10.0% and 4.0% patients had LVI and LNI, respectively. Median follow-up was 42
months (27-58). At 5-years, OS was 96.5% in pL0N0 patients vs 93.1% pL1N0 patients vs 93.3% in pL0N1 patients vs 86.6% pL1N1 patients.
LVI was an independent predictor of OS (hazard ratio [HR]:1.28). LVI showed interaction with LNI, as LVI was associated with a higher
overall-mortality in patients with LNI (HR:1.66), than in patients without LNI (HR:1.22). (all P<0.0001)
Conclusions: Our report highlights the detrimental impact of LVI on OS. Patients with LVI alone fared similarly to patients with LNI
alone. Patients with both LVI and LNI had worse OS than those with only LVI or LNI, implying a synergetic detrimental interaction. Our
findings demonstrate an important utility that LVI can provide in deciding patients’ prognoses. Ó 2021 Published by Elsevier Inc.

KEYWORDS (MeSH): Prostatic neoplasms; prostatectomy; lymphovascular Invasion; lymph node involvement

1. Introduction
Prostate cancer (CaP) is the second-most common cause
of cancer-specific mortality in North American men. Many
CaP patients are treated with radical prostatectomy (RP),
with or without a pelvic lymph node dissection [1-3].
Lymph node invasion (LNI) on surgical specimen is evidence of regional dissemination and possible metastasis
which usually necessitates the use of adjuvant treatments,
and is associated with worse prognosis after RP [4,5].
*Corresponding author: Tel: +1 (348) 735-7124, fax: +1 (313) 916-9539
E-mail address: firas.abdollah@gmail.com (F. Abdollah).

Regional dissemination occurs in 12% of newly diagnosed
CaP cases in the United States[6], and is reasonably
expected to become more prevalent with US Preventative
Task Force recommendations against routine PSA screening [7,8].
The prevalence and significance of LNI underscores the
importance of accurate assessment of LNI after RP. However, the only accurate method for defining a patient’s LNI
status is with histopathological assessment of lymph nodes
after lymphadenectomy following RP. This is further complicated by the lack of an unequivocally identified sentinel
node for CaP [9], the significant morbidity associated with
an all-encompassing lymph node dissection, and the lack of

https://doi.org/10.1016/j.urolonc.2021.01.007
1078-1439/Ó 2021 Published by Elsevier Inc.
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standardization in the number of lymph nodes removed by
various surgeons [10].
On the other hand, lymphovascular invasion (LVI) at
time of RP is recognized as an adverse pathological feature
in patients with prostate cancer [11-14]. Theoretically,
assessment of LVI status should mirror LNI status, and
there have been multiple studies that have identified a
strong link between LVI and LNI [13,15]. Further, several
studies have observed that the presence of LVI was associated with less favorable biochemical recurrence (BCR)
rates [12-14,16]. However, the impact of LVI on overall
survival (OS) and how it compares to other pathological
features has not been documented in the literature. Our
objective was to assess the prognostic ability of LVI and its
potential use as a predictor of OS in a large North American
Cohort.
2. Methods
2.1. Study population
Our cohort was derived from the National Cancer Database (NCDB), a clinical oncology database jointly sponsored by the American College of Surgeons and the
American Cancer Society. The data is sourced from hospital registries leading to data from 1,500 Commission on
Cancer-accredited facilities. The data from the NCDB represents approximately 70% of newly diagnosed cancer
cases across the United States [17].
Within the NCDB, we identified a total of 126,682
patients with histologically confirmed non-metastatic adenocarcinoma of the prostate, diagnosed between 2010 and
2015, who underwent RP with lymph node dissection.
Patients before 2010 were excluded because NCDB did not
record LVI status for these individuals. Patients who
received androgen deprivation therapy (ADT) were
included, in order to mirror the clinical milieu that surrounds these patients.
2.2. Covariates
The following variables were extracted for all patients:
age at diagnosis, serum prostate specific antigen (PSA)
value at diagnosis, baseline Charlson Comorbidity Index
(CCI) category (0, 1, ≥2), pathological tumor stage
(≤pT2, pT3a, pT3b, and pT4), pathological Gleason score
(≤6, 3+4, 4+3, 8, and 9 − 10), surgical margin status (negative or positive), number of nodes removed, number of
positive nodes, pathological LNI status (pN0, pN1), and
pathological LVI status (pL0, pL1). Specifically, LVI was
defined as the presence of tumor cells in lymphatic channels or blood vessels within the primary tumor, but not the
lymph nodes. Lastly, adjuvant radiotherapy (aRT) status
and adjuvant ADT status were also abstracted and
accounted for.

2.3. Endpoints
The main endpoint of this study was OS, defined as the
period in months from diagnosis until death due to any
cause, or last available follow-up. For this cohort, followup data was available through December 31, 2016.
2.4. Statistical analyses
Medians and interquartile ranges (IQRs) were reported
for continuous variables, while proportions and frequencies were reported for categorical variables. The MannWhitney-U test and chi-square tests were used to compare continuous, and categorical variables, respectively.
Kaplan-Meier curves were used to estimate OS. Given
the strong relationship between LNI and LVI reported in
literature [13,15], we divided our patients into four
groups: patients without LVI or LNI (pL0N0), patients
with LVI but no LNI (pL1N0), patients with LNI but no
LVI (pL0N1), and patients with LVI and LNI (pL1N1).
The log-rank test was used to compare OS between these
groups. Cox-regression analysis tested the relationship
between LVI status and OS, after adjusting to all available covariates. We also examined the interaction
between LVI and LNI in the multivariable analysis predicting overall mortality.
All statistical analyses were performed using SAS 9.4
(SAS Institute, Cary, NC). Two-sided statistical significance was defined as a p-value<0.05. An institutional
review board waiver was obtained before the study was
conducted, in accordance with institutional regulation when
dealing with de-identified previously collected data.
3. Results
3.1. Descriptive characteristics
Descriptive data are represented in Table 1. Median
(IQR) age and PSA value at time of diagnosis were 62 (5766) years and 5.9 (4.5-8.9) ng/ml, respectively. Most
patients had pT2 stage disease (68.5%), pathological Gleason 3+4 (46.8%), and negative surgical margins (76.0%).
The median (IQR) of number of nodes removed was 5 (3-9)
nodes. Overall, 10.0% (12,632), 4.0% (5,010), and 2.3%
(2,919) of patients had LVI, LNI, and LVI and LNI, respectively. The median (IQR) of positive nodes in men with
LNI was 1 (1-2) nodes. 4,014 patients received adjuvant
ADT.
Patients with LVI were older (median: 63 vs. 62 years),
had a higher PSA at time of diagnosis (median: 7.5 vs. 5.7),
had a higher rate of ≥ pT3a disease (74.4% vs. 26.5%),
pathological Gleason ≥ 8 disease (46.5% vs. 10.8%), higher
rates of positive surgical margins (43.7% vs. 21.3%), and
LNI (23.3% vs. 1.8%), than their counterparts without LVI
(all P <0.0001).
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Table 1
Descriptive statistics of 126,682 non-metastatic prostate cancer patients treated with radical prostatectomy and lymph node dissection, between 2010 and
2015, within the National Cancer Database
Characteristics

Entire Cohort

No LVI

LVI

P-value

Age (IQR)
Median PSA (IQR)
Regional Lymph Nodes Examined
Regional Lymph Nodes Positive
Age Group
≤50
51 - 59
60 - 69
≥70
Pathologic tumor stage
pT1
pT2
pT3a
pT3b
pT4
Gleason grade
≤6
3+4
4+3
8
9 - 10
Lymph Node Invasion
pNo
pN1
Surgical Margin
Negative Surgical Margin
Positive Surgical Margin
PSA Group
≤4
4 - 10
10 - 20
> 20

62 (57 - 66)
5.9 (4.5 - 8.9)
5 (3 - 9)
0 (0 - 0)

62 (56 - 66)
5.7 (4.4 - 8.5)
5 (3 - 9)
0 (0 - 0)

63 (57 - 67)
7.5 (5.1 - 12.8)
6 (3 - 10)
0 (0 - 0)

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

8,784 (6.9%)
40,370 (31.9%)
62,500 (49.3%)
15,018 (11.9%)

8,097 (7.1)
36,772 (32.2%)
56,082 (49.1%)
13,199 (11.6%)

697 (5.6%)
3,598 (28.7%)
6.418 (51.2%)
1,819 (14.5%)

238 (0.2%)
86,783 (68.5%)
26,868 (21.2%)
12,348 (9.8%)
372 (0.3%)

229 (0.2%)
83,589 (73.2%)
22,833 (20%)
7,239 (6.3%)
196 (0.2%)

9 (0.1%)
3,194 (25.5%)
4,035 (32.2%)
5,109 (40.8%)
176 (1.4%)

23,863 (18.9%)
59,219 (46.8%)
25,480 (20.1%)
7,897 (6.2%)
10,188 (8%)

23,500 (20.6%)
56,521 (49.5%)
21,842 (19.1%)
6,121 (5.4%)
6,137 (5.4%)

363 (2.9%)
2,698 (21.5%)
3,638 (29%)
1,776 (14.2%)
4,051 (32.3%)

121,672 (96.1%)
5,010 (3.9%)

112,059 (98.2%)
2,091 (1.8%)

9,613 (76.7%)
2,919 (23.3%)

96,266 (76.3%)
29,828 (23.7%)

89,287 (78.6%)
24,355 (21.4%)

6,979 (56.0%)
5,473 (44.0%)

29,142 (23%)
74,254 (58.6%)
15,296 (12.1%)
7,990 (6.3%)

26,826 (23.5%)
68,041 (59.6%)
12,936 (11.3%)
6,347 (5.6%)

2,316 (18.5%)
6,213 (49.6%)
2,360 (18.8%)
1,643 (13.1%)

<0.0001

<0.0001

<0.0001
<0.0001
<0.0001

3.2. Overall survival analysis

4. Discussion

Overall, the median (IQR) follow-up of the cohort was
42.0 months (27.0-58.0). At 5-years, the estimated OS rate
was 96.5% in patients with pL0N0 disease vs. 93.1% in
patients with pL1N0 disease vs. 93.3% in patients with
pL0N1 disease, vs. 86.6% in patients with pL1N1 disease
(Fig. 1, log-rank test P <0.0001).

Lymph node dissection remains a necessary tool in the
accurate staging of CaP. However, there is an ongoing
debate about the therapeutic utility of extended pelvic
lymph node dissection [18] as well as multiple difficulties
with regards to its standardization [10], and potential complications [19]. This identifies an important role and benefit
for a prognostic factor that may supplement and complement the prognostic impact of LNI. LVI is an established
adverse pathological finding [11-14] and has a strong relationship/correlation with LNI status [13,15]. Further, it has
also been shown to be an adverse prognostic factor for BCR
[20,21]. However, its impact on OS, which is the most
important oncological endpoint, has not been evaluated.
We set to address this void and evaluate the prognostic role
of LVI in CaP patients.
Our analyses yielded several findings worth highlighting. For example, we observed a detrimental impact of LVI
on OS. At 5-years, the OS-rate was 96.5% in patients with
pL0N0 disease, while it was 93.1% in patients with pL1N0

3.3. Cox regression analysis
On Cox regression analysis, LVI was an independent
predictor of higher overall mortality (hazard ratio [HR]:
1.283, 95% CI: 1.151 − 1.430, P<.0001). The presence of
LVI was also shown to interact significantly with LNI status. Specifically, LVI was associated with a higher risk of
overall mortality in patients with concomitant LNI (HR:
1.657, 95% CI: 1.276 − 2.151, P<.0001), than in patients
without LNI (HR: 1.216, 95% CI: 1.078 − 1.372,
P<.0001). Other covariates that had a detrimental prognostic impact on overall mortality are detailed in Table 2.
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Figure 1. Kaplan-Meier figure depicting survival estimates in all patients vs. patients with lymphovascular invasion vs. lymph node involvement vs.
lymphovascular invasion and lymph node involvement at time of radical prostatectomy, diagnosed between 2010 and 2015, within the National Cancer
Database.

Table 2
Cox regression analysis predicting overall mortality in 126,682 non-metastatic prostate cancer patients treated with radical prostatectomy and pelvic lymph
node dissection, between 2010 and 2015, within the National Cancer Database
Variable

Univariable Analysis

Multivariable Analysis

Hazards Ratio

95% CI

p value

Hazards Ratio

95% CI

P value

1.011
1.06

1.009−1.014
1.054−1.065

<.0001
<.0001

1.004
1.046

1.002−1.007
1.04−1.052

0.0012
<.0001

0
1
2+

Ref
1.762
3.073

1.627−1.908
2.636−3.583

<.0001
<.0001

Ref
1.646
2.676

1.511−1.793
2.267−3.158

<.0001
<.0001

≤6
3+4
4+3
8
9-10

Ref
1.327
1.687
2.235
4.548
1.617

1.19−1.479
1.496−1.903
1.924−2.597
4.039−5.121
1.506−1.738

<.0001
<.0001
<.0001
<.0001
<.0001

Ref
1.211
1.255
1.471
2.431
1.154

1.072−1.368
1.092−1.443
1.237−1.749
2.085−2.833
1.061−1.255

0.0023
0.0019
<.0001
<.0001
0.0008

pT1/2
pT3a
pT3b+

Ref
1.516
2.973
2.795

1.396−1.646
2.731−3.236
2.496−3.131

<.0001
<.0001
<.0001

Ref
1.116
1.519
1.247

1.013−1.229
1.347−1.714
1.079−1.441

0.0368
<.0001
0.0027

2.374

2.183−2.583

<.0001

1.283

1.151−1.43

<.0001

2.06
3.07

1.844−2.301
2.731−3.452

<.0001
<.0001

1.042
1.231

0.908−1.196
1.051−1.441

0.582
0.0094

PSA
Age
CDCC Comorbidity

Gleason Grade

Positive Surgical Margin
Pathologic Stage

Pathologic Positive Lymph Node
Involvement (LNI)
Pathologic Positive Lymphovascular
Invasion (LVI)
Adjuvant Radiotherapy within 1 year of RP
Adjuvant Androgen Deprivation therapy
within 1 year of RP
Legend
PSA: Prostate
Specific Antigen
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disease, indicating less favorable survival in patients with
LVI alone. Patients with LNI, but no LVI, had a similar OS
(93.3%) to those who had LVI, but no LNI. Conversely,
patients that had both LVI and LNI fared worse than
patients who had only one of those two features, as their OS
rate was 86.6%. Such observations ascertain a synergetic
detrimental interaction between LVI and LNI, which was
also confirmed on Cox-Regression Analysis. Our findings
elucidated the prognostic importance of LVI by confirming
that the presence of LVI increased overall mortality risk by
28% within the entire cohort (HR:1.28, P<0.0001). The
increased overall mortality risk was considerably higher
in patients that had concomitant LNI (HR: 1.66,
P<0.0001), compared to patients that did not (HR:1.22,
P<0.0001). Due to the synergetic detrimental interaction
shown by our analyses, LVI should not be considered for
use as a surrogate for LNI, but actually provides important complementary prognostic information of its own
accord. To our best knowledge, our report is the first to
document such findings.
Our results also show that LVI has a similar prognostic
impact to Gleason 4+3 disease and indicates a worse prognosis than the presence of positive surgical margins, or
pT3a disease, all of which carry significant prognostic
weight and indicate adverse pathology. In addition to its
impact on OS, this further establishes the importance of
assessing LVI when determining patient’s prognosis after
RP.
Our study corroborates and adds to several previous
reports on this topic. For example, several prior studies
have established the association between LVI and increased
BCR [12-14,22]. However, our assessment of OS is an
important next step as BCR has recently been shown to not
be an ideal surrogate for OS [23-26]. Our findings are also
the first to show the detrimental prognostic impact of LVI
on OS in a contemporary, large, North American cohort,
adding to prior single [27,28] and multi-institutional studies
[14], as well as a smaller, nationwide Asian cohort [20].
Lastly, while previous reports showed a possible relationship between LVI and LNI, our report is the first to explain
in depth the nature of this relationship. Interestingly, we
found the relationship to be synergistic and not simply additive, which implies a possibly different mechanism of disease spreading in patients with LVI, a point which
definitely warrants further investigation.
Our studies also somewhat contradict the findings of a
previous report by Wilczak et al [16], which assessed the
prognostic value of LVI and whether it may complement or
replace lymph node assessment in clinical practice. While
our findings mirrored theirs in identifying that patients with
LVI alone had similarly unfavorable survival as patients
with LNI alone, in their cohort they identified no significant
difference between patients that had both LNI and LVI and
patients that had only LVI or only LNI. This incongruent
finding may be due to the difference in the examined
cohorts, specifically a nationwide US cohort vs. a single

5

institutional European cohort, exclusion criteria, and/or the
examined endpoints, as we assessed OS, while Wilczak et
al assessed BCR-free survival.
Our study has several limitations. For example, our study
lacks a centralized pathological review. While this is a limitation, contrarily, in some ways it may function as a
strength as it lends reproducibility and applicability of our
results to the clinical practice within the United States. Further, our study might be limited by imprecise nodal status
assessment, as most patients received a limited lymph node
dissection, which is the current practice in the US. Last but
not least, due to the retrospective and observational nature
of our cohort, our results should only be considered as
hypothesis generating. Further due to the retrospective
nature, there is possibility of increased confounding as compared to prospective or randomized controlled studies.
Thus, a univariable analysis alone would be insufficient for
a study of this nature. Our multivariable analysis isolated
and evaluated the prognostic impact of each variable while
adjusting for all other abstracted covariates. Thus, confirming the prognostic impact of various variables, including
the negative impact of LVI (HR:1.283, 95% CI: 1.15 -1.43,
P<.0001).
5. Conclusion
Within a large, contemporary nationwide cohort, men
with LVI had worse OS outcomes when compared to those
without LVI. Moreover, LVI also showed a synergistic
interaction with LNI, leading to considerably increased
mortality risk in patients that have both adverse pathological features. Our findings highlight an important utility that
LVI can provide in deciding a patient’s prognosis following
RP, and further exploration is necessary to determine the
true role of LVI as a prognostic indicator.
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